Arvind Sreedharan
Chief Operating Officer at Neurogene, Inc.
Profile
Arvind Sreedharan is currently the Director at Huntington Study Group and the Senior Vice President-Business Operations at Neurogene, Inc. He has previously worked as the Director-Movement Disorders at Lundbeck, Inc., Vice President-Marketing at Auspex Pharmaceuticals, Inc., and Vice President-US Commercial Operations at Novartis Gene Therapies, Inc. He has also served as a Trustee at Huntington's Disease Society of America.
Mr. Sreedharan completed his undergraduate degree at UNC School of Medicine.
Arvind Sreedharan active positions
| Companies | Position | Start |
|---|---|---|
Neurogene, Inc.
 Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Chief Operating Officer | - |
| Huntington Study Group | Director/Board Member | - |
Former positions of Arvind Sreedharan
| Companies | Position | End |
|---|---|---|
| Huntington's Disease Society of America | Director/Board Member | - |
| AUSPEX PHARMACEUTICALS INC | Sales & Marketing | - |
Lundbeck, Inc.
 Lundbeck, Inc. Pharmaceuticals: MajorHealth Technology Part of Lundbeck Foundation, Lundbeck, Inc. is a pharmaceutical company that produces pharmaceutical preparations. The private company is based in Paramus, NJ. The company was founded by Jeffrey S. Aronin. | Corporate Officer/Principal | - |
| AVEXIS INC | Corporate Officer/Principal | - |
Training of Arvind Sreedharan
| UNC School of Medicine | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Auspex Pharmaceuticals, Inc.
 Auspex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Auspex Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of novel medicines for the treatment of orphan diseases. The company was founded by Sepehr Sarshar, Thomas G. Gant and Manouchehr M. Shahbaz on February 28, 2001 and is headquartered in San Diego, CA. | Health Technology |
Lundbeck, Inc.
Lundbeck, Inc. Pharmaceuticals: MajorHealth Technology Part of Lundbeck Foundation, Lundbeck, Inc. is a pharmaceutical company that produces pharmaceutical preparations. The private company is based in Paramus, NJ. The company was founded by Jeffrey S. Aronin. | Health Technology |
| Huntington's Disease Society of America | |
| Huntington Study Group |
- Stock Market
- Insiders
- Arvind Sreedharan
